Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

News

September 13, 2023
Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis
June 22, 2023
Imcyse joins CLAIMS, a European Health Initiative Project to Make Data-Driven Precision Medicine a Reality for Patients with Multiple Sclerosis
March 01, 2023
Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098 for Type 1 Diabetes
April 13, 2022
Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of Imotope™ IMCY-0141 for Multiple Sclerosis
March 14, 2022
Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference
January 13, 2022
Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study
November 03, 2021
Imcyse Appoints Gene Mack, MBA as Chief Financial Officer
June 24, 2021
Imcyse appoints new Scientific Advisory Board and opens new laboratories for next phase of growth
June 24, 2021
INNODIA is ready for a new phase – clinical trials
February 17, 2021
Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round – Pfizer Joins as Newest Shareholder

Events

Denis Bedoret

Chief Executive Officer

©imcyse 2023